ACTINIUM PHARMACEUTICALS INC

NYSE: ATNM (Actinium Pharmaceuticals, Inc.)

Kemas kini terakhir: 3 hari lalu, 12:14AM

1.61

-0.20 (-11.05%)

Penutupan Terdahulu 1.81
Buka 1.73
Jumlah Dagangan 477,727
Purata Dagangan (3B) 576,891
Modal Pasaran 56,464,632
Harga / Jualan (P/S) 650.84
Harga / Buku (P/B) 1.48
Julat 52 Minggu
1.03 (-36%) — 10.24 (536%)
Tarikh Pendapatan 24 Apr 2025 - 28 Apr 2025
Margin Operasi (TTM) -55,504.94%
EPS Cair (TTM) -1.39
Jumlah Hutang/Ekuiti (D/E MRQ) 4.48%
Nisbah Semasa (MRQ) 10.25
Aliran Tunai Operasi (OCF TTM) -34.81 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -21.49 M
Pulangan Atas Aset (ROA TTM) -32.85%
Pulangan Atas Ekuiti (ROE TTM) -100.05%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Bercampur Bercampur
Biotechnology (Global) Bercampur Bercampur
Stok Actinium Pharmaceuticals, Inc. - -

AISkor Stockmoo

0.0
Konsensus Penganalisis 0.0
Aktiviti Orang Dalam NA
Volatiliti Harga -2.0
Purata Bergerak Teknikal 0.0
Osilator Teknikal 2.0
Purata 0.00

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
ATNM 56 M - - 1.48
PLX 203 M - 65.00 4.68
CYBN 161 M - - 0.880
LCTX 122 M - - 1.46
ANRO 71 M - - 0.360
ARMP 57 M - - 4.06

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple targets in oncology and hematology, including CD45, CD33, HER3, and other. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company is based in New York, New York.

Sektor Healthcare
Industri Biotechnology
% Dimiliki oleh Orang Dalam 1.79%
% Dimiliki oleh Institusi 29.67%

Pemilikan

Nama Tarikh Syer Dipegang
Los Angeles Capital Management Llc 31 Dec 2024 213,950
Squarepoint Ops Llc 31 Dec 2024 183,262

Tiada data dalam julat masa ini.

Tiada data dalam julat masa ini.

Tarikh Jenis Butiran
27 Mar 2025 Pengumuman Actinium Pharmaceuticals Announces ATNM-400 a Novel Non-PSMA Targeting First in Class Prostate Cancer Radiotherapy Leveraging Actinium-225
27 Mar 2025 Pengumuman Actinium Pharmaceuticals Provides Business Update After Presentation at Trump Mar-A-Lago Club Announcing Novel Non-PSMA Prostate Cancer Radiotherapy ATNM-400 and Outlining Revitalized Clinical Pipeline with 2025 Corporate Objectives
26 Mar 2025 Pengumuman Actinium Pharmaceuticals to Present Business Update at Trump Mar-A-Lago Club Today
25 Mar 2025 Pengumuman Actinium Pharmaceuticals to Host KOL Investor Call at 8am ET Today to Highlight Revamped Clinical Programs and Expanded Market Opportunities Including Newly Initiated Actimab-A Solid Tumor Program
24 Mar 2025 Pengumuman Actinium Pharmaceuticals Announces Supply Agreement with Eckert & Ziegler for Ac-225 Radioisotope to Support Comprehensive Development Activities
20 Mar 2025 Pengumuman Actinium Pharmaceuticals Announces Research Collaboration with Memorial Sloan Kettering to Support Further Clinical Expansion of Actimab-A's Backbone Therapy Strategy
19 Mar 2025 Pengumuman Actinium Pharmaceuticals to Host Investor KOL Call with Dr. Ehab Atallah of the Medical College of Wisconsin and Provide a Pipeline Update Highlighting Revamped Clinical Programs and Expanded Market Opportunities for Actimab-A and Iomab-ACT with Clini...
18 Mar 2025 Pengumuman Actinium Pharmaceuticals Announces Clinical Trial Program in Solid Tumors Combining Actimab-A with PD-1 Checkpoint Inhibitors KEYTRUDA® and OPDIVO®
17 Mar 2025 Pengumuman Actinium Pharmaceuticals Announces Publication of Actimab-A + CLAG-M Trial Results in Patients with Relapsed or Refractory Acute Myeloid Leukemia in the Peer-Reviewed Journal Leukemia
12 Mar 2025 Pengumuman Actinium Pharmaceuticals to Participate at the 37th Annual Roth Conference
11 Mar 2025 Pengumuman Actinium Pharmaceuticals Announces Initiation of Actimab-A Triplet Combination Frontline Trial Under NCI CRADA with Venetoclax and Taiho Oncology's Hypomethylating Agent ASTX-727 in Patients with Newly Diagnosed AML
Papar semua
2.532.532.062.061.581.581.111.110.6420.642Mar 20Mar 20Mar 21Mar 21Mar 24Mar 24Mar 25Mar 25Mar 26Mar 26Mar 27Mar 27Mar 28Mar 28Mar 31Mar 31

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

10010075755050252500RSI (14H)
0.2000.2000.1500.1500.1000.1000.0500.0500.0000.000MACD (12, 26, 9)

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda